CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 160 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,875,448 | -52.5% | 322,509 | -41.4% | 0.06% | -53.3% |
Q2 2023 | $18,678,770 | -5.3% | 550,509 | -7.6% | 0.14% | -1.5% |
Q1 2023 | $19,721,491 | -9.4% | 595,509 | +21.9% | 0.14% | -6.8% |
Q4 2022 | $21,771,826 | +85.1% | 488,509 | +16.7% | 0.15% | +77.1% |
Q3 2022 | $11,765,000 | +50.1% | 418,509 | +43.9% | 0.08% | +27.7% |
Q2 2022 | $7,839,000 | -17.1% | 290,794 | +4.8% | 0.06% | +1.6% |
Q1 2022 | $9,451,000 | -36.8% | 277,481 | -28.3% | 0.06% | -32.6% |
Q4 2021 | $14,962,000 | +53.8% | 387,221 | +114.9% | 0.10% | +43.9% |
Q3 2021 | $9,730,000 | -27.2% | 180,222 | -54.9% | 0.07% | -27.5% |
Q2 2021 | $13,365,000 | +130.7% | 399,685 | +16.1% | 0.09% | +89.6% |
Q1 2021 | $5,792,000 | -3.9% | 344,139 | 0.0% | 0.05% | 0.0% |
Q4 2020 | $6,030,000 | – | 344,139 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Octagon Capital Advisors LP | 761,398 | $41,108,000 | 10.12% |
Opaleye Management Inc. | 985,000 | $53,045,000 | 9.91% |
VR Adviser, LLC | 1,098,174 | $59,290,000 | 7.62% |
ACUTA CAPITAL PARTNERS, LLC | 337,500 | $18,222,000 | 6.43% |
TSP Capital Management Group, LLC | 271,429 | $14,654,000 | 5.00% |
Ghost Tree Capital, LLC | 255,000 | $13,767,000 | 4.03% |
COMMODORE CAPITAL LP | 248,207 | $13,401,000 | 3.53% |
RTW INVESTMENTS, LP | 3,908,947 | $211,044,000 | 3.18% |
Ikarian Capital, LLC | 791,600 | $42,741,000 | 3.01% |
Redmile Group, LLC | 3,043,298 | $164,308,000 | 2.87% |